by impaired structure or function of the heart, resulting in decreased cardiac output and/or increased pressures in cardiac cavities during rest or exercise. 2 Patients with HF have poor prognosis, with life expectancies shorter than in patients with breast, colon, or prostate cancers.
PAtIEnts And mEthods All patients with HF hospitalized in the 3rd Department of Cardiology of Silesian Center for Heart Diseases in Zabrze, Poland, between April 2011 and October 2014 were screened (FIGurE 1). Patients with the symptoms of acute HF (de novo or due to decompensation of chronic HF) meeting one of the following clinical criteria entered the COMMIT -AHF (The COnteMporary Modalities In Treatment of Acute Heart Failure) registry: 1) acute left ventricular decompensation with radiological features of increased congestion in the pulmonary circulation; 2) cardiogenic shock; 3) administration of catecholamines; 4) intraaortic balloon pump support; 5) hemodiafiltration; 6) mechanical ventilation; 7) intravenous administration of diuretics for at least 7 days; 8) signs of multiorgan failure (glomerular filtration rate of less than 60 ml/min/1.73 m 2 on admission or during hospitalization, aspartate aminotransferase or alanine transaminase levels more than double the upper limit of normal on admission, or an increase in these levels during hospitalization, and international normalized ratio of less than 2.0 without anticoagulation); and 9) the presence of fluid in the body cavities requiring surgical decompression. [17] [18] [19] The exclusion criterion for the COMMIT -AHF registry was ACS (unstable angina pectoris or myocardial infarction) as a reason for hospitalization. COMMIT -AHF shares the database with the recently published COMMIT -HF registry on patients with HF hospitalized in the same center. 20 The etiology of acute severe HF was determined based on medical history and examinations. 15, 21 The ischemic etiology was diagnosed on the basis of a history of myocardial infarction, prior percutaneous revascularization or coronary artery bypass grafting, and the presence of significant stenoses in epicardial coronary arteries. The nonischemic etiology was diagnosed if HF had developed secondary to conditions other than ischemic heart disease, or if to 60%, respectively. 4 Over 1 million patients are admitted to hospitals in the United States and Europe annually with an initial diagnosis of HF. This accounts for approximately 1% to 2% of all hospitalizations. A high rate (as many as 50%) of patients with an incident of acute decompensation of HF requires rehospitalization within 6 months from the first episode, and each consecutive episode is associated with worse prognosis.
5 The prognosis is especially poor for elderly patients with numerous concomitant diseases, in cardiogenic shock, and with extremely impaired left ventricular systolic function.
6,7 These patients often require advanced diagnostic and therapeutic procedures performed by cardiologists, cardiac surgeons, and intensive care specialists.
Considering etiology, HF is a consequence of an ischemic, nonischemic, or complex heart injury. The most common cause of systolic HF is coronary artery disease, accounting for as many as 70% of cases. 8,9 The causes of nonischemic myocardial injury are mostly hypertension and cardiomyopathies, as well as valvular, metabolic, inflammatory, and systemic diseases. Studies conducted in the 1990s indicated better outcomes and lower mortality rates in patients with nonischemic HF compared with those with ischemic HF, but subsequent studies failed to confirm these results.
10-12 HF associated with acute coronary syndrome (ACS), particularly with myocardial infarction, has been well studied and has been repeatedly the focus of clinical trials, reported in numerous publications.
13,14 However, only a few studies compared patients with acute severe HF according to ischemic or nonischemic etiology.
15,16
In our study, we compared the clinical characteristics, treatments, and outcomes of patients with ischemic and nonischemic etiology of acute severe HF not associated with ACS, hospitalized in a reference cardiac and cardiac surgery center with a full spectrum of diagnostic and therapeutic modalities. Inclusion and exclusion criteria Acute severe heart failure n = 114 (17%) FIGurE 1 Flow chart of patients through the study along with a date of death, were obtained from the database of the National Health Fund for all patients, except for 2 foreign patients. Continuous parameters were presented as the mean and SD, or as the median and interquartile range, and their statistical significance was determined with the t test or the Mann-Whitney test, depending on data distribution. Qualitative parameters were compared using the χ 2 test or the Fisher exact test. Long -term mortality was analyzed using the Kaplan-Meier method and log -rank tests. Independent factors associated with in-hospital and 12 -month mortality were identified using the stepwise multiple logistic and Cox proportional hazard regression, respectively, and the results were presented as odds and hazard ratios with 95% CIs. The etilogy of HF and clinical parameters on admission were included into multivariate models. Additionally, treatment -associated parameters were included into a model of 12 -month mortality. P values of less than 0.05 (double -sided) were considered to be statistically significant. All calculations were done using the Statistica PL software, version 12 (Dell, StatSoft, Round Rock, Texas, United States).
rEsuLts Based on inclusion and exclusion criteria, 114 of 665 patients (17%) hospitalized due to HF were entered into the COMMIT -AHF registry (FIGurE 1). Two patients (2%) met the criteria of both ischemic and nonischemic HF, presenting a complex etiology of myocardial injury. For that reason, they were excluded from further analyses. Finally, 61 patients were analyzed the cause of HF had not been explained. Except for 4 young patients (<40 years) with a very low risk of coronary artery disease, coronary angiography was performed in all patients during the hospitalization prior to admission or during the index hospitalization.
The Acute Physiology and Chronic Health Evaluation -Heart Failure (APACHE -HF) scoring system was used to assess the objective level of severity of acute HF in patients with ischemic and nonischemic HF. 22 This score is based on 8 selected significant parameters obtained from the APACHE II score. One point is given for each of the following parameters: mean arterial pressure ≤90 mm Hg, heart rate ≤110 bpm, serum sodium concentration ≤137 mmol/l, serum potassium concentration ≥4.9 mmol/l, serum creatinine concentration ≥130.8 µmol/l, hematocrit ≤36.9%, age ≥72 years, and the Glasgow Coma Scale ≤13 points. Generally, on the basis of the multivariate Cox regression model and the Kaplan-Meier curves, the more points (from 0 to 8) the patient obtains, the higher the risk of HF events or death during the 90 -day follow -up period.
Patients were diagnosed and treated in a 12 -bed intensive cardiac care unit. They had constant, multispecialty medical care involving specialists in cardiology, anesthesia, intensive care, cardiac surgery, vascular surgery, transplantation, and diabetes care. Depending on clinical indications, the diagnostic and therapeutic process of acute severe HF also involved the use of various forms of mechanical heart support and heart transplantation. Data on patient mortality after discharge, Chronic obstructive pulmonary disease, n (%) 4 (7) 4 (8) 1.0
Prior pacemaker implantation, n (%) 6 (10) 3 (6) 0.51
Prior ICD implantation, n (%) 13 (21) 5 (10) 0.099
Prior CRT -D implantation, n (%) 14 (23) 8 (16) 0.34
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; CRT -D, cardiac resynchronization therapy defibrillator; HF, heart failure; ICD, implantable cardioverter-defibrillator; PCI, percutaneous coronary intervention patients admitted in cardiogenic shock was 2 -fold higher in patients with ischemic etiology compared with those with nonischemic etiology. Patients with ischemic HF were more often admitted after cardiac arrest and with intraaortic balloon pump support. In total, 25% of the patients received an intravenous infusion of catecholamines. Higher creatinine concentrations were measured on admission in patients with ischemic HF. Of note, the mean baseline N -terminal pro -B-type natriuretic peptide (NT -proBNP) concentration was over 9000 pg/ml in both groups. The mean APACHE -HF score on admission was 3.8 points in patients with ischemic HF and 3.4 in those with nonischemic HF (P = 0.095). For the selected echocardiographic parameters presented in tAbLE 2, a lower left ventricular ejection fraction (LVEF; 21%) was noted in patients with ischemic etiology compared with those with nonischemic etiology (27%). Patients in both groups often presented signs of cardiogenic shock or low cardiac output syndrome, and for that reason, they often required inotropes and vasopressors (in many cases, 2 or more inotropes/vasopressors during hospitalization). Data on treatment and procedures are presented in tAbLE 3. Considering the clinical characteristics of the patients, an intensive nonpharmacological therapy was used in both groups, including intraaortic balloon pump, hemodiafiltration, in the ischemic group and 51 in the nonischemic group. Among them, 34 patients (30%) presented symptoms of de novo acute HF, and 78 patients (70%)-symptoms of acute HF due to decompensation of chronic HF. In the group of patients with nonischemic HF, myocardial injury was due to a valvular cause in 43% of the cases, due to arterial hypertension in 18%, due to infective endocarditis in 6%, due to a postinflammatory cause in 4%, due to hypertrophic cardiomyopathy in 4%, due to idiopathic pulmonary hypertension in 4%, and due to amyloidosis in 2%; in the remaining 19% of the cases, the cause was insufficiently documented or unknown (mainly dilated cardiomyopathy, but not genetically confirmed).
The baseline characteristics of the patients are presented in tAbLE 1. Patients with ischemic HF were significantly older (8 years) compared to those with nonischemic HF. Male patients dominated in both groups, and the male -to -female ratio was higher in the ischemic group. Patients with ischemic HF more often had a history of diabetes mellitus, chronic renal disease, hypercholesterolemia, and smoking, and presented a trend for more frequent history of stroke and peripheral artery disease.
Basic hemodynamic parameters on admission, including mean arterial pressure and heart rate, were not significantly different between the groups (tAbLE 2). However, the percentage of of them underwent percutaneous coronary intervention. Among patients with nonischemic HF with severe valvular heart disease, 40% (9 of 22 patients) underwent mitral, aortic, or tricuspid valve surgery. None of the patients had coronary artery bypass grafting. Of all 112 patients, 27 were referred for heart transplantation and 2 of them (ischemic group) required urgent procedure. The remaining 25 patients were referred for elective heart transplantation. No significant differences in adverse events were found between patients with ischemic and nonischemic HF (tAbLE 4). The in-hospital mortality rate was similar in both groups: 25% in the ischemic group and 22% in the nonischemic group. The median hospitalization time was similar in both groups and was less than a month (26 days). In both groups, discharged patients presented signs of HF in functional New York Heart Association (NYHA) classes I through IV. However, patients in the functional NYHA class III predominated, constituting 54% and 46% of the cases in the ischemic and nonischemic groups, respectively (tAbLE 5).
The Kaplan-Meier analysis (FIGurE 2) showed that patients with HF of ischemic etiology died earlier after discharge compared with those with nonischemic etiology. However, the 12 -month mortality rate was similar in both groups, reaching 51% and 44% counting from the admission date, and 34% and 28% counting from the discharge date, in patients with ischemic and nonischemic HF, respectively.
In multivariate models, only higher concentrations of NT -proBNP and lower sodium concentrations on admission were independent factors associated with a higher in -hospital mortality rate. For the 12 -month mortality rate, independent predictors were higher NT -proBNP concentrations, history of renal failure, and concomitant chronic obstructive pulmonary disease on admission (tAbLE 6). dIscussIon The prognosis of patients with HF is poor, particularly of those with severe and advanced HF and with acute clinical symptoms.
3,4 Our analysis of 112 patients from the COMMIT -AHF registry demonstrated that, independently of the cause of myocardial injury and despite the use of a broad spectrum of invasive and noninvasive treatments, the mortality of patients with acute severe HF remains high, and 1 in 4 patients dies during hospitalization. In our 12 -month follow -up (starting from the admission date), death was reported for nearly half of the patients with ischemic HF (51%) and nonischemic HF (44%). Undoubtedly, high in -hospital and long -term mortality rates are associated with the clinical profile of the patients. According to established criteria, only patients with highly advanced HF symptoms, with multiorgan failure, and usually in the decompensation phase of HF, were included in the registry. It is a unique population in that there have been no such analyses mechanical ventilation, and implantation of pacemakers or decompression of the pleural cavity, with no significant differences in the frequency of those procedures between the groups. As a direct consequence of the study design, patients with ischemic etiology were more often subject to coronary angiography, after which nearly half Abbreviations: see tAbLE 1 vs nonischemic) affected total mortality, and the mortality was 18% in the 1 -year follow -up. 24 Of note, in our registry, patients with ischemic etiology of acute severe HF were on average 8 years older and were admitted in a more severe condition than patients with a nonischemic etiology. Not surprisingly, risk factors for coronary artery disease were more common in the ischemic group. Lourenco et al 15 analyzed a cohort of 286 patients with advanced HF in 2 groups: with ischemic acute HF (n = 109) and with nonischemic acute HF (n = 177). The clinical characteristics observed in this study in terms of the distribution of age and sex were similar to those in our analysis. In both groups, approximately 60% of patients showed multiorgan failure on admission and during hospitalization. Together with high NT -proBNP levels, this indicates a highly elevated risk of unfavorable clinical outcome, which was confirmed in the current and previous studies.
25-27
Treatment methods used in patients with ischemic and nonischemic HF were different in terms of the intensity of pharmacological treatment and use of various invasive therapeutic procedures. Percutaneous coronary interventions were performed in some patients in the ischemic group. Patients in the nonischemic group were more intensely treated with intravenous inotropes and/or vasopressors. Considering the various hemodynamic profiles of patients (ie, dominating signs of fluid retention, low cardiac output or even cardiogenic shock), an appropriate strategy of intensive pharmacotherapy based on diuretics, vasodilators, inotropes, vasoconstrictors, and intraaortic balloon pump was used. Of note, 5 patients had left ventricular assist device implants and 2 others were referred for heart transplantation. The low prescription rate of angiotensin--converting -enzyme inhibitors and angiotensin receptor blockers at discharge resulted mainly from hypotension, hyperkalemia, renal failure or intolerance to this type of drugs.
Among the numerous analyzed parameters, the multivariate analysis demonstrated that higher NT -proBNP and lower sodium concentrations on admission were independent factors associated with in -hospital mortality. From a pathophysiological point of view, increased levels of natriuretic peptides reflect acute or chronic high pressures in cardiac chambers and abnormal sodium concentrations indicate cardiorenal syndrome. The significance of hyponatremia as an independent predictor of death was confirmed in numerous studies. 15, 17, 28, 29 On the other hand, higher NT -proBNP concentrations on admission, chronic renal failure, and chronic obstructive pulmonary disease were independent risk factors of death during a 12 -month follow -up, which was confirmed by other analyses.
30-32
Our study has several limitations. Our population of the most severely ill patients with HF was treated in a single center with a full range of diagnostic and therapeutic facilities; therefore, the results of the therapy in a similar group in other in Poland to date. Among the very few comparable reports, the CONSENSUS trial revealed that the 1 -year mortality rate was 50% among the 253 patients with congestive HF in the functional NYHA class IV. 16 In the COMMIT -AHF registry, the ischemic etiology was linked with approximately half of the cases of acute severe HF hospitalized in the reference cardiac and cardiac surgery center and had no significant effect on outcome, both in -hospital and during 1 year after discharge. Interestingly, patients from the ischemic group died earlier after discharge compared with those from the nonischemic group, as revealed in the Kaplan-Meier survival curves.
Studies completed over several decades have not elucidated whether the etiology of HF affects prognosis. The majority of those studies involved patients with HF in different clinical conditions (functional NYHA classes II-IV), which hinders a comparative analysis with a group of patients with acute severe HF.
10-12, 23 Bradley et al 18 demonstrated that in 3787 patients with a LVEF of 40% or lower and confirmed as having ischemic or nonischemic HF by coronary angiography (25% and 57% of the patients were in the NYHA classes III and IV, respectively), ischemic etiology of HF was an independent, unfavorable prognostic factor of 5 -year mortality (P <0.0001). Laurenco et al 15 demonstrated a higher in -hospital mortality of patients in the ischemic group compared with those in the nonischemic group (11.0% vs 4.0%, P = 0.02), although no significant differences in long -term survival were noted (70.0% vs 76.8%, P = 0.258). 15 On the other hand, the SOLVD trial, 24 involving over 6000 patients with symptomatic HF and a LVEF of 35% or lower, failed to demonstrate that the etiology of HF (ischemic Abbreviations: ACEI, angiotensin -converting -enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; others, see tAbLE 1 conclusions HF remains a challenge for modern healthcare systems and requires a comprehensive and multidisciplinary approach. Increasingly effective diagnostic and therapeutic methods undoubtedly result in extended life expectancies centers may be different. Moreover, our study sample was quite small. That is why, we cannot draw a definitive conclusion as to whether acute severe HF of ischemic and nonischemic etiologies have similar outcomes. 
